This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the market potential of Vanda's Hetlioz in Jet Lag, prior to the upcoming Phase 2 data release

Ticker(s): VNDA

Who's the expert?

A sleep disorder specialist with experience prescribing Hetlioz for Non-24-Hour Sleep-Wake Disorder or other circadian rhythm disorders.

Interview Questions
Q1.

Please tell us about your experience in treating sleep disorders. How many of your patients experience problems with jet-lag?

Added By: c_admin
Q2.

How different is Hetlioz compared to regular melatonin medicine? What is its mechanism of action?

Added By: c_admin
Q3.

Would it work if taken as a one-off, like a sleeping pill, on-demand by the patient? How quickly does its effect take place? Is it within hours, or does it require prolonged use for days before its effect kicks in?

Added By: c_admin
Q4.

Would you have any worries regarding toxicity? An experiment showed increased cancer risk and fertility impairments in rodents; does this concern you?

Added By: c_admin
Q5.

How common have the adverse effects of urinary tract infection or headache been for your patients taking Hetlioz? And how severe were they?

Added By: c_admin
Q6.

With regard to using Hetlioz for non-24,  reversion to baseline sleep performance happens 1 month after Hetlioz discontinuation. How would this be modified for patients using this drug for jet-lag?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.